PBH
PBH
US74112D1019
Prestige Consumer Healthcare In
Loading chart...

Company Profile

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Latest News

Related stocks

BCRX
BCRX • United States
BioCryst Pharmaceuticals, Inc.
8.55 USD
2.18B USD 1Y +13.9%
SUPN
SUPN • United States
Supernus Pharmaceuticals, Inc.
42.67 USD
2.48B USD 1Y -12.2%
LQDA
LQDA • United States
Liquidia Corporation
27.38 USD
2.45B USD 1Y +16.4%
PAHC
PAHC • United States
Phibro Animal Health Corporatio
38.3 USD
1.56B USD 1Y +0.8%
ANIP
ANIP • United States
ANI Pharmaceuticals, Inc.
73.89 USD
1.7B USD 1Y -21.5%
PCRX
PCRX • United States
Pacira BioSciences, Inc.
36.31 USD
1.45B USD 1Y +55.4%
XERS
XERS • United States
Xeris Biopharma Holdings, Inc.
10.48 USD
1.91B USD 1Y +24.3%
HROW
HROW • United States
Harrow, Inc.
29.36 USD
1.1B USD 1Y -23.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
26.9% p.a.
Max Drawdown (5Y)
-49.8%
Sharpe Ratio (5Y)
-0.23
Beta Factor
0.34
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Historical Stress Test: Maximum peak-to-trough drawdown of -53.8% in the extended horizon.
ende